Item 7.01 Regulation FD Disclosure

On January 8, 2020, Adaptive Biotechnologies Corporation (the "Company") issued a press release announcing that Palmetto GBA, a Medicare Administrative Contractor that assesses diagnostic technologies through its MolDX program, has expanded coverage of the clonoSEQ Assay to include Medicare patients with chronic lymphocytic leukemia, or CLL. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits.




              Exhibit No.   Description of Exhibits

              99.1            Press Release dated January 8, 2020

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses